PADI2 and acute myeloid leukemia: The findings advise that PAD2 is essential for maintaining ER homeostasis and mobile survival, indicating that inhibiting PAD2 with BB-Cl-A may also provide a promising therapeutic approach for AML [118] (Table 2).